{"id":"W1984705525","doi":"10.1053/j.gastro.2013.05.048","title":"Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis","year":2013,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":928,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"UCB Pharma; Genentech; Norgine; Dr. Falk Pharma; Pfizer; Bristol-Myers Squibb","keywords":"Golimumab; Ulcerative colitis; Medicine; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Vedolizumab; Adverse effect; Clinical trial; Randomization; Tumor necrosis factor alpha; Adalimumab; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006204841344557701,"score_gpt":0.2372061494167541,"score_spread":0.2310013080721964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}